Cargando…
Effect on Germline Mutation Rate in a High-Risk Chinese Breast Cancer Cohort after Compliance with The National Comprehensive Cancer Network (NCCN) 2023 v.1 Testing Criteria
SIMPLE SUMMARY: The NCCN Clinical Practice Guidelines are testing criteria used to identify high-risk individuals associated with an increased risk of breast, ovarian, pancreatic, and prostate cancer. The testing criteria have been recently modified in early 2023. In this study, we provided a real-w...
Autores principales: | Kwong, Ava, Ho, Cecilia Y. S., Luk, Wing-Pan, Fung, Ling-Hiu, Au, Chun-Hang, Ma, Edmond S. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177488/ https://www.ncbi.nlm.nih.gov/pubmed/37174101 http://dx.doi.org/10.3390/cancers15092635 |
Ejemplares similares
-
Germline mutations in Chinese ovarian cancer with or without breast cancer
por: Kwong, Ava, et al.
Publicado: (2022) -
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient
por: Kwong, Ava, et al.
Publicado: (2021) -
NCCN Imaging Appropriate Use Criteria Compendium: An Overview
por: Hagaman, Mistie G.
Publicado: (2017) -
Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
por: Kwong, Ava, et al.
Publicado: (2020) -
Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)